
Reuters reported that Pfizer Inc (NYSE:PFE) said it would not run any new clinical trials in Russia and would stop recruiting for existing trials there.
Pfizer said it would work with the FDA and other regulators to transition all clinical trials to alternative sites outside Russia. It will continue providing drugs to the patients already enrolled in studies.